These new findings are in line with what we would expect, and we have seen that these outcomes are evident in patients with Type 2 diabetes and obesity and in patients with obesity without Type 2 diabetes," said Cheryl Bushnell, M.D., M.H.S., FAHA, professor and vice chair of research in the department of neurology at Wake Forest University School of Medicine in Winston-Salem, North Carolina
52 Patients with MASH and F2/F3 stage fibrosis were treated with tirzepatide at doses of 5 mg, 10 mg, and 15 mg for 52 weeks, of which 58% of patients had T2DM
Nutrients, 13(4), 1317
Clinical Perspectives: Maintenance and Long-Term Success Prominent UK obesity specialists, such as Professor Rachel Batterham (UCL) and Professor Susan Jebb (Oxford), have emphasized that while these drugs are game-changers, they are not quick fixes
Can I get retatrutide on the NHS
What works for one person may not be suitable for another, and what seems beneficial in isolation could have unintended consequences when combined with other treatments
